Fierce Pharma
JULY 29, 2024
Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. | Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition.
MedCity News
JULY 29, 2024
As the FDA stakes its claim as the primary regulator of AI in healthcare, it must navigate the delicate balance between fostering innovation and ensuring safety and responsibility. The post Enabling Clinical Trial Innovation Through AI Regulation at FDA appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 29, 2024
With a phase 3 trial win claimed by AstraZeneca, the heated BTK inhibitor race might see its first triplet regimen in chronic lymphocytic leukemia (CLL). | With a phase 3 win claimed by AstraZeneca, the heated BTK inhibitor race might see its first triplet regimen in chronic lymphocytic leukemia.
PharmaTimes
JULY 29, 2024
Coronary heart disease is the most common form of heart and circulatory disease
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JULY 29, 2024
Suboxone maker Indivior has spent years dealing with allegations related to its role in the United States opioid epidemic, inking several settlements over that span and even witnessing its former C | More than a dozen states linked up on the agreement after accusing Indivior of fueling the opioid epidemic with its opioid addiction treatment Suboxone.
pharmaphorum
JULY 29, 2024
Ipsen gets CHMP backing for Alagille syndrome therapy odevixibat, with a new brand name that it hopes will unlock orphan status in the EU
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JULY 29, 2024
Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.The alliance with Health Innovation Oxford & Thames Valley (Oxford HIN) is focusing on Care for MDD, an app-based DTx that has been co-developed by Otsuka and digital health specialist Click Therapeutics.
Fierce Pharma
JULY 29, 2024
A month after a CDC panel narrowed its recommendations for RSV vaccines, Airfinity has reduced the projected market size in the US by 64%.
MedCity News
JULY 29, 2024
Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments. The post GSK, Flagship Pioneering Commit $150M to Start R&D Pact for Novel Drugs and Vaccines appeared first on MedCity News.
pharmaphorum
JULY 29, 2024
Flagship Pioneering signs another strategic-level deal with a big pharma group, with GSK agreeing an alliance potentially worth more than $7 billion
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
JULY 29, 2024
Hospitals all over the country were affected by the recent IT outage caused by CrowdStrike’s software update. The incident is estimated to have costed Fortune 500 companies in the healthcare sector about $2 billion. The post 4 Things to Know About the CrowdStrike IT Outage’s Effect on Healthcare appeared first on MedCity News.
pharmaphorum
JULY 29, 2024
NICE and pharma groups AstraZeneca and Daiichi Sankyo have been unable to agree on a price for Enhertu in HER2-low breast cancer.
MedCity News
JULY 29, 2024
In this episode, we’re joined by Stacey Missmer, professor and associate chair for epidemiology and translational research at the University of Michigan. She discusses a report she recently co-authored that calls on the NIH to improve research on chronic conditions affecting women. The post MedCity FemFwd: The Lack of Research on Chronic Conditions Affecting Women appeared first on MedCity News.
pharmaphorum
JULY 29, 2024
Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and investors.The BROOKLYN study compared the oral CETP inhibitor to a placebo given on top of maximum tolerated doses of other lipid-modifying therapies, like statins and ezetimibe, in patients with heterozygous familial hypercholesterolaemia (HeFH), a genetic condition that raises blood cholesterol and the risk of hea
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
JULY 29, 2024
America is in the midst of a loneliness epidemic and it’s taking a devastating toll on our mental and physical well-being. Here are 3 things that could help reverse the crisis. The post America’s Loneliness Epidemic is Fueling a Mental Health Crisis appeared first on MedCity News.
Pharmaceutical Commerce
JULY 29, 2024
A cohort study investigates whether or not the prevalence of these types of illnesses can vary among individuals who are COVID-positive versus negative.
MedCity News
JULY 29, 2024
The enduring legacy of the Ebola crisis serves as a poignant reminder of our shared responsibility in safeguarding public health and preventing future pandemics. The post What the Ebola Outbreak Reveals about Pandemic Preparedness appeared first on MedCity News.
Pharmaceutical Technology
JULY 29, 2024
EMA’s COMP has adopted positive opinions for two orphan medicinal product designations for Attralus’s AT-02.
pharmaphorum
JULY 29, 2024
AstraZeneca's Calquence hits the mark in the AMPLIFY combination trial in CLL, which could unlock a blockbuster opportunity for the BTK inhibitor
Pharmaceutical Technology
JULY 29, 2024
Clinical trial trends point to studying combination therapies and lifestyle changes using alternate designs in Alzheimer’s research.
PharmaTimes
JULY 29, 2024
The neurodegenerative condition is recognised as the most common form of dementia
Pharmaceutical Technology
JULY 29, 2024
Bristol Myers Squibb (BMS) has posted net income attributable to the company of $1.7bn during Q2 2024, a 19% drop versus $2.1bn in Q2 2023.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaVoice
JULY 29, 2024
A brain-on-a-chip developer says better preclinical modeling could help move the needle.
Pharmaceutical Technology
JULY 29, 2024
The US FDA has granted approval for Luye Pharma’s ERZOFRI extended-release injectable suspension for schizophrenia in adults.
MedCity News
JULY 29, 2024
A new KFF report detailed the growth in Medicare Advantage’s share of total inpatient hospital days. The post Report: MA Beneficiaries Represent Growing Share of Inpatient Hospital Days appeared first on MedCity News.
Pharmaceutical Technology
JULY 29, 2024
The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.
Pharmacy Times
JULY 29, 2024
Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.
Pharmaceutical Technology
JULY 29, 2024
Osteoporosis is the most common metabolic bone disorder worldwide and is the leading cause of fragility fractures.
Pharmacy Times
JULY 29, 2024
Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.
European Pharmaceutical Review
JULY 29, 2024
The Committee for Medicinal Products for Human Use (CHMP) has recommended against a marketing authorisation for Leqembi (lecanemab), as a treatment for Alzheimer’s disease, during its July meeting last week. They concluded that considering the “observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine, in particular the frequent occurrence of amyloid-related imaging abnormalities (ARIA), involving swelling and p
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
312 
Let's personalize your content